PITTSBORO, N.C., Jan. 4 /PRNewswire/ -- Biolex Therapeutics today announced that it will be presenting at the 25th Annual JPMorgan Healthcare Conference on Thursday, January 11, 2007, at 1:30 p.m. PST in the Elizabethan C/D room of the Westin St. Francis Hotel in San Francisco. During the presentation Biolex will provide a corporate overview, including an update regarding the clinical development of Locteron(TM), its lead candidate for the treatment of hepatitis C.

About Biolex Therapeutics

Biolex Therapeutics is developing and commercializing therapeutic proteins based on its proprietary LEX System(SM), an expression system that enables the production of hard-to-make proteins and the optimization of monoclonal antibodies. The Company is developing a proprietary pipeline of products that rely upon known mechanisms of action to provide a reduced risk profile while targeting large, proven pharmaceutical markets. Biolex's lead candidate, Locteron(TM), is being developed as a best-in-class controlled-release interferon alfa for the treatment of hepatitis C. The Company's second product candidate, BLX-155, is a direct-acting thrombolytic, designed to break up clots in certain diseases such as acute peripheral arterial disease, catheter occlusion and deep vein thrombosis. In addition, the unique capabilities of the LEX System have led to collaborations with Centocor, Medarex and other leading pharmaceutical/biotech companies. Biolex is a venture-capital-backed company located in the Research Triangle region of North Carolina, United States. For additional information, please visit Biolex's web site at www.biolex.com.

SOURCE Biolex Therapeutics